Monopar presents preclinical uPAR-targeted radiopharma data at SNMMI; Phase 1 trial ongoing

Monopar Therapeutics

Data show robust tumor uptake of MNPR-101-Zr in triple-negative breast, colorectal, and pancreatic cancer mouse models.
Construct optimized for higher tumor uptake and stability with minimal bone and healthy tissue accumulation.
First-in-human Phase 1 imaging/dosimetry trial in advanced cancer patients recently initiated led by Prof. Rodney Hicks.
Trial details available on ClinicalTrials.gov under identifier NCT06337084.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.